Therefore, the efficacy of PD-1/PD-L1 therapy is dependent upon the activity of tumor-reactive T lymphocytes in eradicating tumors, which is associated with the levels of PD-L1 expression, tumor mutational burden (TMB) and microsatellite instability (MSI), TILs and mismatch repair deficiencies. The gene discussed is CD274; the disease is neoplasm.